Papillary renal cell carcinoma (pRCC) is the 2nd most frequent histological type of kidney cancer and accounts for approximately 15% of all renal cell carcinoma. It has a poorer prognosis than clear cell RCC (ccRCC) with a lack of standard treatments.
We report the case of a 51 year old man with a metastatic pRCC (hepatic dome and left colonic peritoneal carcinomatosis) progressive after sunitinib, with a MET amplification. The patient was enrolled in the UNICANCER-sponsored AcSé crizotinib trial (NCT02034981), designed to give an access to crizotinib for patients with tumors harboring a genomic alteration on one of the biological targets of the drug. With 2nd line crizotinib (250 mg twice/day), the patient had a very good tolerance, a partial response in the target lesions using RECIST 1.1, and a 19 months' clinical efficacy.
In metastatic pRCC with a MET amplification, crizotinib maybe a potential met-inhibitory therapeutic option.
BMC cancer. 2018 Nov 22*** epublish ***
Philippe Rochigneux, Jeanne Thomassin-Piana, Sophy Laibe, Serge Brunelle, Naji Salem, Bernard Escudier, Gilles Vassal, Gwenaelle Gravis
Department of Medical Oncology, Institut Paoli-Calmettes, 232 Bd de Sainte-Marguerite, 13009, Marseille, France. ., Department of Pathology, Institut Paoli-Calmettes, Marseille, France., Department of Cytogenetics and Molecular Genetics, Institut Paoli-Calmettes, Marseille, France., Department of Radiology, Institut Paoli-Calmettes, Marseille, France., Department of Radiotherapy, Institut Paoli-Calmettes, Marseille, France., Department of Medical Oncology, Gustave Roussy Cancer Center, Villejuif, France., Direction of Clinical Research, Gustave Roussy Cancer Center, Villejuif, France., Department of Medical Oncology, Institut Paoli-Calmettes, 232 Bd de Sainte-Marguerite, 13009, Marseille, France.